+1 347 708 0418
The Peripheral Arterial Disease (PAD) Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Peripheral Arterial Disease (PAD) Therapeutics size is estimated to be USD 3693.1 million in 2026 from USD 3025.1 million in 2020, with a change XX% between 2020 and 2021. The global Peripheral Arterial Disease (PAD) Therapeutics market size is expected to grow at a CAGR of 5.1% for the next five years.
Market segmentation
Peripheral Arterial Disease (PAD) Therapeutics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Anti-Platelet Drugs
Dual Antiplatelet Therapy Drugs
Others
Market segment by Application, can be divided into
Hospitals
Clinics
Others
Market segment by players, this report covers
AstraZeneca Plc. (UK)
Bayer HealthCare Pharmaceuticals (Germany)
Bristol-Myers Squibb Company (US)
Merck & Co., Inc. (US)
Proteon Therapeutics, Inc. (US)
Sanofi S.A. (France)
Symic Bio, Inc. (US)
TheraVasc Inc. (US)
AnGes MG, Inc. (Japan)
Athersys, Inc. (US)
Betagenon AB (Sweden)
miRagen Therapeutics, Inc. (US)
Multi Gene Vascular Systems Ltd (Israel)
ViroMed Co. Ltd. (Korea)
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Peripheral Arterial Disease (PAD) Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Peripheral Arterial Disease (PAD) Therapeutics, with revenue, gross margin and global market share of Peripheral Arterial Disease (PAD) Therapeutics from 2019 to 2021.
Chapter 3, the Peripheral Arterial Disease (PAD) Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Peripheral Arterial Disease (PAD) Therapeutics market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Peripheral Arterial Disease (PAD) Therapeutics research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Product Overview and Scope of Peripheral Arterial Disease (PAD) Therapeutics
1.2 Classification of Peripheral Arterial Disease (PAD) Therapeutics by Type
1.2.1 Overview: Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Type in 2020
1.2.3 Anti-Platelet Drugs
1.2.4 Dual Antiplatelet Therapy Drugs
1.2.5 Others
1.3 Global Peripheral Arterial Disease (PAD) Therapeutics Market by Application
1.3.1 Overview: Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size & Forecast
1.5 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size and Forecast by Region
1.5.1 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region, (2016-2021)
1.5.3 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size and Prospect (2016-2026)
1.5.4 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size and Prospect (2016-2026)
1.5.6 South America Peripheral Arterial Disease (PAD) Therapeutics Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Peripheral Arterial Disease (PAD) Therapeutics Market Drivers
1.6.2 Peripheral Arterial Disease (PAD) Therapeutics Market Restraints
1.6.3 Peripheral Arterial Disease (PAD) Therapeutics Trends Analysis
2 Company Profiles
2.1 AstraZeneca Plc. (UK)
2.1.1 AstraZeneca Plc. (UK) Details
2.1.2 AstraZeneca Plc. (UK) Major Business
2.1.3 AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
2.1.4 AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 AstraZeneca Plc. (UK) Recent Developments and Future Plans
2.2 Bayer HealthCare Pharmaceuticals (Germany)
2.2.1 Bayer HealthCare Pharmaceuticals (Germany) Details
2.2.2 Bayer HealthCare Pharmaceuticals (Germany) Major Business
2.2.3 Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
2.2.4 Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Bayer HealthCare Pharmaceuticals (Germany) Recent Developments and Future Plans
2.3 Bristol-Myers Squibb Company (US)
2.3.1 Bristol-Myers Squibb Company (US) Details
2.3.2 Bristol-Myers Squibb Company (US) Major Business
2.3.3 Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
2.3.4 Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Bristol-Myers Squibb Company (US) Recent Developments and Future Plans
2.4 Merck & Co., Inc. (US)
2.4.1 Merck & Co., Inc. (US) Details
2.4.2 Merck & Co., Inc. (US) Major Business
2.4.3 Merck & Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
2.4.4 Merck & Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Merck & Co., Inc. (US) Recent Developments and Future Plans
2.5 Proteon Therapeutics, Inc. (US)
2.5.1 Proteon Therapeutics, Inc. (US) Details
2.5.2 Proteon Therapeutics, Inc. (US) Major Business
2.5.3 Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
2.5.4 Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Proteon Therapeutics, Inc. (US) Recent Developments and Future Plans
2.6 Sanofi S.A. (France)
2.6.1 Sanofi S.A. (France) Details
2.6.2 Sanofi S.A. (France) Major Business
2.6.3 Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
2.6.4 Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Sanofi S.A. (France) Recent Developments and Future Plans
2.7 Symic Bio, Inc. (US)
2.7.1 Symic Bio, Inc. (US) Details
2.7.2 Symic Bio, Inc. (US) Major Business
2.7.3 Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
2.7.4 Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Symic Bio, Inc. (US) Recent Developments and Future Plans
2.8 TheraVasc Inc. (US)
2.8.1 TheraVasc Inc. (US) Details
2.8.2 TheraVasc Inc. (US) Major Business
2.8.3 TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
2.8.4 TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 TheraVasc Inc. (US) Recent Developments and Future Plans
2.9 AnGes MG, Inc. (Japan)
2.9.1 AnGes MG, Inc. (Japan) Details
2.9.2 AnGes MG, Inc. (Japan) Major Business
2.9.3 AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
2.9.4 AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 AnGes MG, Inc. (Japan) Recent Developments and Future Plans
2.10 Athersys, Inc. (US)
2.10.1 Athersys, Inc. (US) Details
2.10.2 Athersys, Inc. (US) Major Business
2.10.3 Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
2.10.4 Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Athersys, Inc. (US) Recent Developments and Future Plans
2.11 Betagenon AB (Sweden)
2.11.1 Betagenon AB (Sweden) Details
2.11.2 Betagenon AB (Sweden) Major Business
2.11.3 Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
2.11.4 Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Betagenon AB (Sweden) Recent Developments and Future Plans
2.12 miRagen Therapeutics, Inc. (US)
2.12.1 miRagen Therapeutics, Inc. (US) Details
2.12.2 miRagen Therapeutics, Inc. (US) Major Business
2.12.3 miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
2.12.4 miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 miRagen Therapeutics, Inc. (US) Recent Developments and Future Plans
2.13 Multi Gene Vascular Systems Ltd (Israel)
2.13.1 Multi Gene Vascular Systems Ltd (Israel) Details
2.13.2 Multi Gene Vascular Systems Ltd (Israel) Major Business
2.13.3 Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
2.13.4 Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 Multi Gene Vascular Systems Ltd (Israel) Recent Developments and Future Plans
2.14 ViroMed Co. Ltd. (Korea)
2.14.1 ViroMed Co. Ltd. (Korea) Details
2.14.2 ViroMed Co. Ltd. (Korea) Major Business
2.14.3 ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
2.14.4 ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 ViroMed Co. Ltd. (Korea) Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Peripheral Arterial Disease (PAD) Therapeutics Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Peripheral Arterial Disease (PAD) Therapeutics Players Market Share
3.2.2 Top 10 Peripheral Arterial Disease (PAD) Therapeutics Players Market Share
3.2.3 Market Competition Trend
3.3 Peripheral Arterial Disease (PAD) Therapeutics Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Peripheral Arterial Disease (PAD) Therapeutics Revenue and Market Share by Type (2016-2021)
4.2 Global Peripheral Arterial Disease (PAD) Therapeutics Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Application (2016-2021)
5.2 Peripheral Arterial Disease (PAD) Therapeutics Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Peripheral Arterial Disease (PAD) Therapeutics Revenue by Type (2016-2026)
6.2 North America Peripheral Arterial Disease (PAD) Therapeutics Revenue by Application (2016-2026)
6.3 North America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country
6.3.1 North America Peripheral Arterial Disease (PAD) Therapeutics Revenue by Country (2016-2026)
6.3.2 United States Peripheral Arterial Disease (PAD) Therapeutics Market Size and Forecast (2016-2026)
6.3.3 Canada Peripheral Arterial Disease (PAD) Therapeutics Market Size and Forecast (2016-2026)
6.3.4 Mexico Peripheral Arterial Disease (PAD) Therapeutics Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Peripheral Arterial Disease (PAD) Therapeutics Revenue by Type (2016-2026)
7.2 Europe Peripheral Arterial Disease (PAD) Therapeutics Revenue by Application (2016-2026)
7.3 Europe Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country
7.3.1 Europe Peripheral Arterial Disease (PAD) Therapeutics Revenue by Country (2016-2026)
7.3.2 Germany Peripheral Arterial Disease (PAD) Therapeutics Market Size and Forecast (2016-2026)
7.3.3 France Peripheral Arterial Disease (PAD) Therapeutics Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Peripheral Arterial Disease (PAD) Therapeutics Market Size and Forecast (2016-2026)
7.3.5 Russia Peripheral Arterial Disease (PAD) Therapeutics Market Size and Forecast (2016-2026)
7.3.6 Italy Peripheral Arterial Disease (PAD) Therapeutics Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Revenue by Type (2016-2026)
8.2 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Revenue by Application (2016-2026)
8.3 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Market Size by Region
8.3.1 Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Revenue by Region (2016-2026)
8.3.2 China Peripheral Arterial Disease (PAD) Therapeutics Market Size and Forecast (2016-2026)
8.3.3 Japan Peripheral Arterial Disease (PAD) Therapeutics Market Size and Forecast (2016-2026)
8.3.4 South Korea Peripheral Arterial Disease (PAD) Therapeutics Market Size and Forecast (2016-2026)
8.3.5 India Peripheral Arterial Disease (PAD) Therapeutics Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Market Size and Forecast (2016-2026)
8.3.7 Australia Peripheral Arterial Disease (PAD) Therapeutics Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Peripheral Arterial Disease (PAD) Therapeutics Revenue by Type (2016-2026)
9.2 South America Peripheral Arterial Disease (PAD) Therapeutics Revenue by Application (2016-2026)
9.3 South America Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country
9.3.1 South America Peripheral Arterial Disease (PAD) Therapeutics Revenue by Country (2016-2026)
9.3.2 Brazil Peripheral Arterial Disease (PAD) Therapeutics Market Size and Forecast (2016-2026)
9.3.3 Argentina Peripheral Arterial Disease (PAD) Therapeutics Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Revenue by Type (2016-2026)
10.2 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Revenue by Application (2016-2026)
10.3 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Market Size by Country
10.3.1 Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Revenue by Country (2016-2026)
10.3.2 Turkey Peripheral Arterial Disease (PAD) Therapeutics Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Peripheral Arterial Disease (PAD) Therapeutics Market Size and Forecast (2016-2026)
10.3.4 UAE Peripheral Arterial Disease (PAD) Therapeutics Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Peripheral Arterial Disease (PAD) Therapeutics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue (USD Million) by Region (2016-2021)
Table 5. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Region (2021-2026)
Table 6. AstraZeneca Plc. (UK) Corporate Information, Head Office, and Major Competitors
Table 7. AstraZeneca Plc. (UK) Major Business
Table 8. AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
Table 9. AstraZeneca Plc. (UK) Peripheral Arterial Disease (PAD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Bayer HealthCare Pharmaceuticals (Germany) Corporate Information, Head Office, and Major Competitors
Table 11. Bayer HealthCare Pharmaceuticals (Germany) Major Business
Table 12. Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
Table 13. Bayer HealthCare Pharmaceuticals (Germany) Peripheral Arterial Disease (PAD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Bristol-Myers Squibb Company (US) Corporate Information, Head Office, and Major Competitors
Table 15. Bristol-Myers Squibb Company (US) Major Business
Table 16. Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
Table 17. Bristol-Myers Squibb Company (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Merck & Co., Inc. (US) Corporate Information, Head Office, and Major Competitors
Table 19. Merck & Co., Inc. (US) Major Business
Table 20. Merck & Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
Table 21. Merck & Co., Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Proteon Therapeutics, Inc. (US) Corporate Information, Head Office, and Major Competitors
Table 23. Proteon Therapeutics, Inc. (US) Major Business
Table 24. Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
Table 25. Proteon Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Sanofi S.A. (France) Corporate Information, Head Office, and Major Competitors
Table 27. Sanofi S.A. (France) Major Business
Table 28. Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
Table 29. Sanofi S.A. (France) Peripheral Arterial Disease (PAD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Symic Bio, Inc. (US) Corporate Information, Head Office, and Major Competitors
Table 31. Symic Bio, Inc. (US) Major Business
Table 32. Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
Table 33. Symic Bio, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. TheraVasc Inc. (US) Corporate Information, Head Office, and Major Competitors
Table 35. TheraVasc Inc. (US) Major Business
Table 36. TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
Table 37. TheraVasc Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. AnGes MG, Inc. (Japan) Corporate Information, Head Office, and Major Competitors
Table 39. AnGes MG, Inc. (Japan) Major Business
Table 40. AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
Table 41. AnGes MG, Inc. (Japan) Peripheral Arterial Disease (PAD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Athersys, Inc. (US) Corporate Information, Head Office, and Major Competitors
Table 43. Athersys, Inc. (US) Major Business
Table 44. Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
Table 45. Athersys, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Betagenon AB (Sweden) Corporate Information, Head Office, and Major Competitors
Table 47. Betagenon AB (Sweden) Major Business
Table 48. Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
Table 49. Betagenon AB (Sweden) Peripheral Arterial Disease (PAD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. miRagen Therapeutics, Inc. (US) Corporate Information, Head Office, and Major Competitors
Table 51. miRagen Therapeutics, Inc. (US) Major Business
Table 52. miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
Table 53. miRagen Therapeutics, Inc. (US) Peripheral Arterial Disease (PAD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Multi Gene Vascular Systems Ltd (Israel) Corporate Information, Head Office, and Major Competitors
Table 55. Multi Gene Vascular Systems Ltd (Israel) Major Business
Table 56. Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
Table 57. Multi Gene Vascular Systems Ltd (Israel) Peripheral Arterial Disease (PAD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. ViroMed Co. Ltd. (Korea) Corporate Information, Head Office, and Major Competitors
Table 59. ViroMed Co. Ltd. (Korea) Major Business
Table 60. ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Product and Solutions
Table 61. ViroMed Co. Ltd. (Korea) Peripheral Arterial Disease (PAD) Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue (USD Million) by Players (2019-2021)
Table 63. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Share by Players (2019-2021)
Table 64. Breakdown of Peripheral Arterial Disease (PAD) Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 65. Peripheral Arterial Disease (PAD) Therapeutics Players Head Office, Products and Services Provided
Table 66. Peripheral Arterial Disease (PAD) Therapeutics Mergers & Acquisitions in the Past Five Years
Table 67. Peripheral Arterial Disease (PAD) Therapeutics New Entrants and Expansion Plans
Table 68. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue (USD Million) by Type (2016-2021)
Table 69. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Share by Type (2016-2021)
Table 70. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Forecast by Type (2021-2026)
Table 71. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue by Application (2016-2021)
Table 72. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Forecast by Application (2021-2026)
Table 73. North America Peripheral Arterial Disease (PAD) Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 74. North America Peripheral Arterial Disease (PAD) Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 75. North America Peripheral Arterial Disease (PAD) Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 76. North America Peripheral Arterial Disease (PAD) Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 77. North America Peripheral Arterial Disease (PAD) Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 78. North America Peripheral Arterial Disease (PAD) Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 79. Europe Peripheral Arterial Disease (PAD) Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 80. Europe Peripheral Arterial Disease (PAD) Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 81. Europe Peripheral Arterial Disease (PAD) Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 82. Europe Peripheral Arterial Disease (PAD) Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 83. Europe Peripheral Arterial Disease (PAD) Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 84. Europe Peripheral Arterial Disease (PAD) Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 85. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 86. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 87. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 88. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 89. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Revenue by Region (2016-2021) & (USD Million)
Table 90. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Revenue by Region (2021-2026) & (USD Million)
Table 91. South America Peripheral Arterial Disease (PAD) Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 92. South America Peripheral Arterial Disease (PAD) Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 93. South America Peripheral Arterial Disease (PAD) Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 94. South America Peripheral Arterial Disease (PAD) Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 95. South America Peripheral Arterial Disease (PAD) Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 96. South America Peripheral Arterial Disease (PAD) Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 97. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 98. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 99. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 100. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 101. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 102. Middle East & Africa Peripheral Arterial Disease (PAD) Therapeutics Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Peripheral Arterial Disease (PAD) Therapeutics Picture
Figure 2. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Type in 2020
Figure 3. Anti-Platelet Drugs
Figure 4. Dual Antiplatelet Therapy Drugs
Figure 5. Others
Figure 6. Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Application in 2020
Figure 7. Hospitals Picture
Figure 8. Clinics Picture
Figure 9. Others Picture
Figure 10. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 11. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue and Forecast (2016-2026) & (USD Million)
Figure 12. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Region (2016-2026)
Figure 13. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Region in 2020
Figure 14. North America Peripheral Arterial Disease (PAD) Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Europe Peripheral Arterial Disease (PAD) Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. South America Peripheral Arterial Disease (PAD) Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. Middle East and Africa Peripheral Arterial Disease (PAD) Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Peripheral Arterial Disease (PAD) Therapeutics Market Drivers
Figure 20. Peripheral Arterial Disease (PAD) Therapeutics Market Restraints
Figure 21. Peripheral Arterial Disease (PAD) Therapeutics Market Trends
Figure 22. AstraZeneca Plc. (UK) Recent Developments and Future Plans
Figure 23. Bayer HealthCare Pharmaceuticals (Germany) Recent Developments and Future Plans
Figure 24. Bristol-Myers Squibb Company (US) Recent Developments and Future Plans
Figure 25. Merck & Co., Inc. (US) Recent Developments and Future Plans
Figure 26. Proteon Therapeutics, Inc. (US) Recent Developments and Future Plans
Figure 27. Sanofi S.A. (France) Recent Developments and Future Plans
Figure 28. Symic Bio, Inc. (US) Recent Developments and Future Plans
Figure 29. TheraVasc Inc. (US) Recent Developments and Future Plans
Figure 30. AnGes MG, Inc. (Japan) Recent Developments and Future Plans
Figure 31. Athersys, Inc. (US) Recent Developments and Future Plans
Figure 32. Betagenon AB (Sweden) Recent Developments and Future Plans
Figure 33. miRagen Therapeutics, Inc. (US) Recent Developments and Future Plans
Figure 34. Multi Gene Vascular Systems Ltd (Israel) Recent Developments and Future Plans
Figure 35. ViroMed Co. Ltd. (Korea) Recent Developments and Future Plans
Figure 36. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Share by Players in 2020
Figure 37. Peripheral Arterial Disease (PAD) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 38. Global Top 3 Players Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share in 2020
Figure 39. Global Top 10 Players Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share in 2020
Figure 40. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 41. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Share by Type in 2020
Figure 42. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share Forecast by Type (2021-2026)
Figure 43. Global Peripheral Arterial Disease (PAD) Therapeutics Revenue Share by Application in 2020
Figure 44. Global Peripheral Arterial Disease (PAD) Therapeutics Market Share Forecast by Application (2021-2026)
Figure 45. North America Peripheral Arterial Disease (PAD) Therapeutics Sales Market Share by Type (2016-2026)
Figure 46. North America Peripheral Arterial Disease (PAD) Therapeutics Sales Market Share by Application (2016-2026)
Figure 47. North America Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Country (2016-2026)
Figure 48. United States Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Canada Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Mexico Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Europe Peripheral Arterial Disease (PAD) Therapeutics Sales Market Share by Type (2016-2026)
Figure 52. Europe Peripheral Arterial Disease (PAD) Therapeutics Sales Market Share by Application (2016-2026)
Figure 53. Europe Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Country (2016-2026)
Figure 54. Germany Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. France Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. United Kingdom Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Russia Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Italy Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Sales Market Share by Type (2016-2026)
Figure 60. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Sales Market Share by Application (2016-2026)
Figure 61. Asia-Pacific Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Region (2016-2026)
Figure 62. China Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Japan Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. South Korea Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. India Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Southeast Asia Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Australia Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. South America Peripheral Arterial Disease (PAD) Therapeutics Sales Market Share by Type (2016-2026)
Figure 69. South America Peripheral Arterial Disease (PAD) Therapeutics Sales Market Share by Application (2016-2026)
Figure 70. South America Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Country (2016-2026)
Figure 71. Brazil Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Argentina Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Middle East and Africa Peripheral Arterial Disease (PAD) Therapeutics Sales Market Share by Type (2016-2026)
Figure 74. Middle East and Africa Peripheral Arterial Disease (PAD) Therapeutics Sales Market Share by Application (2016-2026)
Figure 75. Middle East and Africa Peripheral Arterial Disease (PAD) Therapeutics Revenue Market Share by Country (2016-2026)
Figure 76. Turkey Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Saudi Arabia Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. UAE Peripheral Arterial Disease (PAD) Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Methodology
Figure 80. Research Process and Data Source
Buy
